source
- Beren Therapeutics secures $300 million to fund rare disease drug launch ahead of FDA reviewBeren Therapeutics announced it has raised $300 million in new financing to support the development and launch of its rare disease therapy. The funding arrives as the company prepares for an FDA d…
- Novartis inks second molecular glue partnership with Orionis, $40M upfrontNovartis has entered a second agreement with Orionis Biosciences focused on molecular glue technology. The deal includes an upfront payment of $40 million. The agreement also provides for mileston…